Back to EZorb Newsletter Index

In this issue:

1. Share Success: Letters From Readers
2. Research News: Intermittent Fasting Beneficial for Type 2 diabetes
3. Useful Links
4. What Are Others Saying About EZorb and Marvlix?

Letter I: From Sandra S.
Received at Testimonial Submit Form Saturday, October 29, 2022 at 09:15 AM PDT
(Unedited)

Hi, my name is Sandra. I had arthritis in my knees which was making my life miserable. Every morning I would apply something to both knees to make them a little more comfortable.

I decided to type it into search “is there a cure for arthritis” expecting a no answer, but found your site instead. Decided to order and try.

After about 6 weeks I suddenly realized that I had not applied anything to knees and it was close to dinner time. I have not found the need to do that ever since.

Now I tell everyone I can. Thank you so much for the amazing product.

Letter II: From Linda
Received at Testimonial Submit Form Friday, October 28, 2022 at 05:10 AM PDT
(Unedited)

Hi, my name is Linda. I began taking Ezorb about 1 year ago after having knee replacement surgery on my left knee. Bone on bone on right knee but did not want another surgery.

I started taking Ezorb powder and within 2 months felt less pain & better movement. Now I am pain free and feel as though I have a new knee.

Thank you for a great product that actually does what it claims to do!

Our newsletter reaches over 200,000 subscribers worldwide. Success stories you shared in the past have made a great impact on many people's life.

Please email your story to sharesuccess @ ezorbonline.com or simply post it to Testimonial Submit Form. Your personal information will never be revealed to the public.

A randomized trial reveals benefits of intermittent fasting, without an increased risk for severe hypoglycemia, in people with insulin-treated type 2 diabetes.

“For some individuals, intermittent fasting appears to be an easy to apply dietary intervention without the need for continuous caloric reductions, ultimately leading to reduced caloric intake through the time-restricted eating pattern without vigorous documentation or calorie counting,” say the researchers in Diabetes Care.

At baseline, the 22 participants assigned to the intermittent fasting group had an average glycated hemoglobin (HbA1c) level of 69 mmol/mol (8.5%). Over the course of 12 weeks, they fasted for 3 nonconsecutive days/week, reducing their calorie intake by 75% on these days, and ate as they wished on the remaining 4 days.

This resulted in an average 7.3 mmol/mol HbA1c reduction, which was significant versus the change in the 24 control group participants, who continued with their usual diet, and experienced an average 0.1 mmol/mol increase in HbA1c from a baseline of 66 mmol/mol (8.2%).

All participants used a flash glucose monitor for the duration of the trial, and those in the intermittent fasting group were instructed to reduce their basal insulin dose by 20% on fasting days and to use prandial insulin only if needed to correct hyperglycemia. They continued with any other medications bar sulfonylurea. There were no episodes of serious hypoglycemia during the study, and of the five serious adverse events (two in the fasting group), none were thought to be related to the intervention.

Harald Sourij (Medical University of Graz, Austria) and co-researchers note that on fasting days the study participants were permitted to spread 25% of their total daily calorie allowance across breakfast and/or lunch, rather than eating it during one meal, in order to minimize hypoglycemia risk and study dropout.

“With our study data we would feel confident to omit this caloric intake in further studies,” they observe.

All trial participants were switched to the same basal insulin (glargine U300) before randomization, which was taken in the morning. The average total daily insulin dose in the fasting group was 52 IU at baseline, and this declined to 45 IU during the 12-week intervention period, whereas it rose from 59 to 63 IU in the control group, with the difference between the two being statistically significant.

Bodyweight also decreased with intermittent fasting, by an average of 4.77 kg from a baseline of 96 kg, which was again a significant change relative to the average 0.27 kg increase observed in the control group from a baseline of 104 kg.

Original research was published in Diabetes Care 2022; doi:10.2337/dc22-1622.

EZorb - Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

Back to EZorb Newsletter Index